When Pat Sullivan joined Insulet (NSDQ:PODD) in 2014, the Billerica, Mass.-based company was reeling in roughly $300 million in revenue selling its Omnipod tubless insulin delivery system. Sullivan, a veteran of the medtech industry, saw a path to creating a billion-dollar company and it centered around the concept of making life easier for people with diabetes.
“I have an attraction to bringing new and innovative technology to market and I was totally enamored with the Omnipod. I understood why this product should be the standard of care in insulin delivery and I’ve been working for the last four years to make that happen,” he told Drug Delivery Business News.
Get the full story at our sister site, Drug Delivery Business News.
The post How Insulet’s CEO plans to create a billion-dollar business appeared first on MassDevice.